Alkermes releases nine-month data as OX2R race heats up
Alkermes’ oral, selective orexin 2 receptor (OX2R) agonist has shown continued benefit nine months after the start of treatment in…
Central Nervous System
-
-
Roche culls development of two Huntington’s disease programmes
Roche has stopped development of two of its Huntington’s disease candidates after one failed to show benefit in a Phase…
-
Compass’ psilocybin shows six-month durability in Phase III trial
Compass Pathways’ psilocybin-based therapy has continued to show benefit after six months in a Phase III trial in treatment-resistant depression…
-
EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
-
EAN 2026: Meta-analysis finds no added benefit of Radicava/Rilutek combo in ALS
A systematic review and meta-analysis evaluating whether using Daiichi Sankyo’s Radicava (edaravone) and Sanofi’s Rilutek (riluzole) in combination provides additional…
-
NeuroSense’s ALS drug cuts key biomarker in Phase IIb trial
Massachusetts-based biotech NeuroSense Therapeutics’ combination amyotrophic lateral sclerosis (ALS) therapy, PrimeC, has been shown to reduce a key biomarker of…
-
Otsuka’s ADHD drug reduces symptoms in Phase IIIb trial
Otsuka’s daily attention-deficit/hyperactivity disorder (ADHD) candidate has shown benefit in a Phase IIIb trial. In the study (NCT06973577), centanafadine XR…
-
Three pivotal MDD trial failures for Neumora lead to staffing cuts
Neumora Therapeutics is cutting its staff by 35% following Phase III trial failures of its multiple depressive disorder (MDD) candidate.…
-
Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation
On 30 April 2026, Axsome Therapeutics announced the FDA approval of Auvelity (dextromethorphan + bupropion) for the treatment of agitation…
-
Corcept’s ALS drug demonstrates two-year benefit despite primary endpoint miss
Corcept Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has shown two-year survival benefit above placebo, despite the trial having failed to…
